Meiji Yasuda Asset Management Co Ltd. Buys 512 Shares of DexCom, Inc. (NASDAQ:DXCM)

Meiji Yasuda Asset Management Co Ltd. lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 9.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,976 shares of the medical device company’s stock after purchasing an additional 512 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in DexCom were worth $678,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Crewe Advisors LLC bought a new stake in DexCom in the 1st quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the second quarter valued at $25,000. DSM Capital Partners LLC purchased a new position in shares of DexCom in the fourth quarter valued at $28,000. Riverview Trust Co bought a new stake in DexCom in the first quarter worth $32,000. Finally, Sachetta LLC raised its stake in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Trading Down 2.1 %

Shares of DXCM opened at $70.43 on Friday. The firm has a market capitalization of $28.01 billion, a price-to-earnings ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a 50-day moving average of $78.19 and a 200 day moving average of $109.63.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the firm posted $0.34 earnings per share. The company’s revenue was up 15.3% on a year-over-year basis. On average, research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on DXCM shares. Barclays dropped their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective on the stock. Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $145.00 to $75.00 in a report on Friday, July 26th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,483 shares of company stock worth $201,708. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.